December 9, 2019 09:35 AM ESTUpdated 04:04 PM
R&D

KalVis­ta's di­a­bet­ic mac­u­lar ede­ma da­ta falls short — will Mer­ck walk away?

Natalie Grover

Reporter

Mer­ck’s 2017 bet on KalVista Phar­ma­ceu­ti­cals may have soured, af­ter the UK/US-based biotech’s lead drug failed a mid-stage study in pa­tients with di­a­bet­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times